Potential Therapeutic Benefit of the Selective Inhibitors of Casitas B Cell Lymphoma-b (CBL-B) in Cancer Immunotherapy

Abstract

The invention in this patent application relates to 1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one derivatives represented generally by formula 1. These compounds are inhibitors of the E3 ubiquitin ligase, casitas B-lineage lymphoma proto-oncogene-b (CBL-B), and may be useful for the treatment of immunosuppression-associated diseases and disorders such as cancer and chronic viral infections.Biological Data. The following table contains some of the biological data obtained from testing the above representative examples. Recent ReviewArticles. See refs 1−5.